Expert Review of Hematology· 2026Q2· Review
Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia
- 0citations
- Q2SCImago
- 2026year
Short summary
Most acute myeloid leukemia (AML) patients treated with menin inhibitors like revumenib relapse within months due to resistance mechanisms including on-target MEN1 mutations, clonal evolution, and adaptive signals, with limited treatment options post-failure.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Genetics
GeneticsMedicine